-
About
-
Health
I Want to...
Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
-
Patient Care
I Want To...
-
Research
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
-
School of Medicine
I Want to...
Or find a doctor at another Johns Hopkins Medicine Member Hospital:
Jerry Le Pow Spivak, M.D.

Director, Center for the Chronic Myeloproliferative Disorders
Professor of Medicine
Male
Expertise: Anemias, Chronic Myeloid Leukemia (CML), Erythrocytosis, Essential Thrombocytosis, Hematology, Hypereosinophilia, Leukopenia, Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis, Systematic Mastocytosis ...read more
Research Interests: Myeloproliferative disorders; Essential thrombocytosis; Polycythemia vera; Primary myelofibrosis
Request an Appointment
I live in Maryland
410-955-3142
Request an appointment through My
I live outside of Maryland
410-464-6641
Request Appointment
I live outside of the United States
+1-410-502-7683
Request Appointment
Locations
The Johns Hopkins Hospital (Main Entrance)
Appointment Phone: 410-955-3142
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
map
Background
Jerry L. Spivak, MD, is currently Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine. Dr. Spivak is a graduate of Cornell University Medical College and received training in Internal Medicine, Hematology and Oncology at the Johns Hopkins Hospital, New York Hospital, and the National Cancer Institute. Board certified in Internal Medicine and Hematology, Dr. Spivak was Director of the Hematology Division at Johns Hopkins from 1980 to 1992. He is currently the Director of the Johns Hopkins Center for The Chronic Myeloproliferative Disorders.
An author of over 250 publications and the recipient of a Research Career Development Award and a Merit Award from the National Institutes of Health, Dr. Spivak's research and clinical interests include erythropoiesis, erythropoietin, and the chronic myeloproliferative disorders.
Titles
- Director, Center for the Chronic Myeloproliferative Disorders
- Professor of Medicine
Departments / Divisions
Centers & Institutes
- Chronic Myeloproliferative Disorders Center
- Sidney Kimmel Comprehensive Cancer Center
Education
Degrees
- MD, Cornell University Medical College (1964)
Board Certifications
- American Board of Internal Medicine / Hematology (1974)
- American Board of Internal Medicine / Internal Medicine (1971)
Research & Publications
Research Summary
Dr. Spivak's research interests are focused on the chronic myeloproliferative disorders with particular emphasis on the molecular basis of these disorders and the means for distinguishing them both diagnostically and with respect to therapeutic intervention. Using techniques to analyze gene expression in polycythemia vera stem cells, he has found that polycythemia vera patients can be distinguished from patients with erythrocytosis and also divided into two groups, those with an aggressive disease and those with a more indolent illness. Dr. Spivak and his colleagues are also studying the role of specific molecular markers identified at Johns Hopkins and elsewhere with respect to the pathogenesis of polycythemia vera as well as its diagnosis.
Selected Publications
250 publications as of 2014.
Activities & Honors
Honors
- Phi Beta Kappa
- Alpha Omega Alpha
- NIH Research Career Development Award
- NIH Merit Award
Memberships
- American Clinical and Climatological Society
- American Society of Hematology
- Fellow of the American College of Physicians
- International Society of Experimental Hematology
- International Society of Hematology
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
Comments